You've successfully subscribed to NeuroXT
Great! Next, complete checkout for full access to NeuroXT
Welcome back! You've successfully signed in.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info is updated.
Billing info update failed.

NEXT-SCN

World-first multimodal platform that measures in-vivo synaptic integrity to objectively verify the impact of synapse-targeted therapies.

MRI → NN → Amyloid → Tau

Synapse Targeted Therapeutics Efficacy Validation

Multimodal model for quantifying Synaptic Integrity in vivo to validate efficacy of synapse targeted therapeutics (World’s first)

Prediction screenshot

Compared to other products, NeuroXT's NEXT-ATN shows superior amyloid positive prediction accuracy and demonstrates excellent performance in tau stage prediction.